Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Abstract Background PD-1/PD-L1 inhibitors are promising approaches for advanced Merkel cell carcinoma (MCC). Nevertheless, these inhibitors bear a high risk for induction of immune-related adverse events (irAEs), particularly flares of preexisting autoimmune diseases. Neurological irAEs of PD-1/PD-L...

Full description

Bibliographic Details
Main Authors: Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, Saskia Bolz, Selma Sirin, Martin Glas, Jürgen C. Becker, Selma Ugurel, Alexander Roesch, Dirk Schadendorf, Elisabeth Livingstone, Tim Hagenacker, Lisa Zimmer
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Merkel cell carcinoma
Myasthenia gravis
Immune checkpoint inhibitor
Adverse events
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0626-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0626-9

Similar Items